AGP Picks
View all

Cloud-Clone highlights active ACE2 protein for disease research

7 hours ago
Cloud-Clone highlights active ACE2 protein for disease research
By AI, Created 05:24 UTC, Nov 17, 2026, AGP -

Cloud-Clone is promoting a recombinant active ACE2 protein for research tied to cardiovascular disease, kidney injury, fibrosis and virus-host interaction. The company says the reagent is functionally validated for binding and activity studies, including work involving coronavirus spike protein and pre-clinical drug discovery.

Why it matters: - ACE2 sits at the center of two major research areas: the renin-angiotensin system and coronavirus host-cell entry. - A well-folded, catalytically active ACE2 reagent can support studies of cardiovascular protection, renal homeostasis, fibrosis and viral binding in the same workflow. - Researchers also use ACE2-based assays to screen peptides, antibodies and small molecules for therapeutic development.

What happened: - Cloud-Clone introduced a recombinant active ACE2 protein for in-vitro research use. - The product is positioned for studies in cardiorenal disease, organ fibrosis, host-virus interaction and peptide drug development. - The company says the reagent is functionally validated and designed to preserve enzymatic activity and receptor-binding capacity.

The details: - ACE2 converts angiotensin II into angiotensin 1-7, which supports vasodilation, anti-inflammatory signaling and anti-fibrotic effects. - ACE2 is expressed in alveolar epithelial cells, cardiomyocytes, renal tubular epithelial cells, intestinal epithelial cells and vascular endothelial cells. - ACE2 can also be cleaved into soluble circulating sACE2, which participates in systemic signaling. - ACE2 also acts as a host-cell attachment site for coronaviruses, including HCoV-NL63, SARS-CoV and SARS-CoV-2. - Cloud-Clone says it used optimized eukaryotic expression and purification workflows to produce the protein. - The company says the product has low endotoxin levels and consistent batch-to-batch performance. - The protein is supplied as sterile vacuum-lyophilized material. - Cloud-Clone says short-term ambient-temperature transport does not reduce functional performance. - Repeated freeze-thaw cycles should be limited to fewer than three times to preserve enzyme activity. - The protein re-dissolves readily without visible precipitation.

Between the lines: - The release is aimed at researchers who need both enzymatic activity and spike-protein binding in one reagent. - That matters because misfolded ACE2 can distort binding assays, enzyme-kinetics results and neutralization studies. - The company is also framing ACE2 as a bridge between basic biology and pre-clinical screening, not just as a viral receptor.

What's next: - Researchers can use the reagent for enzyme-activity assays, ELISA, surface plasmon resonance, biolayer interferometry, pseudovirus neutralization tests and cell-function studies. - Cloud-Clone says the product can also support antibody generation, structural biology and high-throughput screening of ACE2-modulating compounds. - The company says technical support is available from its team.

The bottom line: - Cloud-Clone is betting that validated active ACE2 protein will be a useful tool for labs studying cardiovascular disease, fibrosis, kidney injury and virus-host interactions.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Technology Press Releases

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Technology Press Releases

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.